UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies. Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.
Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.
Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.
Return to Rheumatology Homepage
Rheumatoid Arthritis
Cholesterol
Dermatomyositis
Gout
Lupus
Psoriatic Arthritis
Scleroderma
Vasculitis
If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.
If you are interested in finding out more information of a particular study, please contact the study personnel.
Study Type | Title of Study | |
| Rheumatoid Arthritis | ||
| Treatment/ Interventional | *Multiple studies | Principal Investigators |
| Treatment/Interventional | Dietary Intervention on Rheumatoid Arthritis Assessed by Ultrasound in over weight patients Status: Open for Enrollment | Principal Investigator Veena K. Ranganath, MD, MS For more information, please contact (310) 825-9956 |
| Treatment/Interventional | Musculoskeletal Ultrasound Predicting Therapeutic Response in Tofacitinib in Rheumatoid Arthritis Patients Status: Open for Enrollment | Principal Investigator Veena K. Ranganath, MD, MS For more information, contact (310) 825-9956 |
| Observational | HDL (Carotid Study): Evaluation of HDL function in patients with and without Rheumatic Disease Status: Open for Enrollment | Principal Investigator Christina Charles, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Treatment | BMS: A Placebo-Controlled Study to Evaluate the Effect, Safety, and Characteristics of Abatacept in Subjects with Rheumatoid Arthritis with Hepatitis B. Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 |
| Treatment | Use of ACTHAR in Rheumatoid Arthritis Related Flares. Status: Open for Enrollment | Principal Investigator Veena K. Ranganath, MD, MS For more information, contact (310) 825-9956 |
| Cholesterol | ||
| Observational | HDL Function in Patients With and Without Rheumatic Disease (Investigatory) | Principal Investigator Christina Charles-Schoeman, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Dermatomyositis | ||
| Treatment | Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients with Dermatomyositis Status: Open for Enrollment | Principal Investigator Christina Charles-Schoeman, MD For more information, contact Jeraldine Guzman |
| Gout | ||
| Observational | Gout Cholesterol Study: A study to evaluate the association between gout and cholesterol. Patients undergo blood draw and Dual Energy CAT Scan (to measure amount of gouty deposits). | Principal Investigators John FitzGerald, MD For more information, contact (310) 794-5100 |
| Lupus | ||
| Treatment | Efficacy of Abatacept (Orencia®) in inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE) Status: Open for Enrollment | Principal Investigator Bevra Hahn, MD For more information contact |
| Treatment | Rituximab plus Cyclophosphamide followed by Belimumab for the treatment of Lupus Nephritis (CALIBRATE) Status: Open for Enrollment | Principal Investigators Maureen McMahon, MD For more information contact |
| Treatment | Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (STOP RA) Status: Open for Enrollment | Principal Investigators For more information contact |
| Treatment | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with active Proliferative Lupus Nephritis Status: Open for Enrollment | Principal Investigator Jennifer Grossman, MD For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Treatment | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating Efficacy and Safety of Anifrolumab in Adult subjects with Active Systemic Lupus Erythematosus (SLE) Status: Open for Enrollment | Principal Investigator Jennifer Grossman, MD For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Observational | Biomarkers in Lupus Status: Open for Enrollment | Principal Investigator Ram Raj Singh, MD For more information contact Ram Raj Singh, MD |
| Observational | The Role of Gender Factors in Lupus and Autoimmunity Status: Open for Enrollment | Principal Investigator For more information contact |
| Observational | Autoimmunity Characteristics in Patients with Systemic Lupus Erythematosus versus Health Controls Status: Open for Enrollment | Principal Investigator For more information contact |
| Observational | Observational, Mechanisms of Inflammation and Immune Response in Skin Dermatoses. Status: Open for Enrollment | Principal Investigator For more information contact |
| Treatment/ Interventional | *Multiple studies Status: Open for Enrollment | Principal Investigators For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Treatment | Novartis: CAIN457F2354 AIN457/Secukinumab (Cosentyx) for Active Psoriatic Arthritis. Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744 |
| Scleroderma | ||
| Treatment/ Interventional | *Multiple studies | Principal Investigator TBD |
| Observational | SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Status: Open for Enrollment
| Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 |
| Observational | Blood and Skin Biopsy Donation: A research study to define the differences in Immune Responses in skin from patients with an autoimmune or inflammatory condition Status: Open for Enrollment | Principal Investigator For more information, contact |
| Other | PHAROS: Outcome Studies in Systemic Sclerosis: A Prospective Database of Echocardiograms and PFTs on Patients with Limited Scleroderma (Standard of Care) Status: Open for Enrollment | Principal Investigators For more information, contact Nashla Barroso (310) 825-9682 |
| Observational | Quality of Life: Quality of Life of people with scleroderma: Health values and minimally important differences of people with scleroderma Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact Nashla Barroso (310) 825-9682 |
| Treatment | BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis. Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 |
| Treatment | Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 |
| Observational | GRASP: Genome Research in African American Scleroderma Patients (GRASP) Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744 |
| Treatment | SLS III: A Combination study of Pirfenidone (PFD) with Mycophenolate (MMF) for Treating Scleroderma-Related Lung Disease. Status: Open for Enrollment | Principal Investigator Co-Investigator Suzanne Kafaja, MD For more information, contact Nashla Barroso (310) 825-9682 |
| Treatment | STAT: Scleroderma Treatment with Autologous Transplant (STAT). A study of a Scleroderma Treatment Using the Patient's Own Blood Stem Cells. Status: Open for Enrollment | Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744 |
| Treatment | Corbus JBT101-SSc-002: A phase 3 study to assess the safety and efficacy of Lenabasum in patients with Scleroderma. Lenabasum is an experimental drug that may reduce inflammation and stop the development of scar tissue (fibrosis) that results from chronic active inflammation. While there are no known treatments that can repair the damage already done, lenabasum may reduce or resolve disease symptoms and prevent further damage to tissue and organs in patients with chronic over-active inflammatory and fibrotic diseases such as scleroderma. Status: Open for Enrollment
| Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744 |
| Vasculitis | ||
| Treatment | A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine Lay person title: Study of an Investigaional Treatment for ANCA Vasculitis This is a clinical trial evaluating an investigational product called CCX168 (also known as Avacopan) in patients with granulomatosis with polyangiitis (GPA, formerly called Wegener’s disease) and microscopic polyangiitis (MPA). Status: Open for Enrollment | Principal Investigator For more information contact, Tandy Ramirez 310-206-0994 |
| Other | Clinical Transcriptomics in Systemic Vasculitis (CUTIS). This is a multi-center study evaluating new ways to distinguish different forms of vasculitis that can affect the skin by evaluation of biopsy and laboratory testing. Status: Open for Enrollment | Principal Investigator Tanaz Kermani, MD (Rheumatology and Dr. Bonita Kozma (Dermatology) For more information, contact Tandy Ramirez at 310-206-0994 |
